Background Every year around the world, more than 2 million women are diagnosed with
breast cancer and genital tract cancers. However, there are rare studies comprehensively …

Background. Leukemia is a common malignancy that has four main subtypes and is a threat
to human health. Understanding the epidemiological status of leukemia and its four main …

Over the last two decades, the introduction of targeted therapies and the advances in the
detection of BCR: ABL1 oncogene have dramatically improved comprehensive care for …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with increasing incidence
worldwide. Growing evidence suggests that ubiquitin-specific proteases (USPs) play a role …

PURPOSE To map the magnitudes and temporal trends of chronic myeloid leukemia (CML)
along with its attributable risk factors, providing the essential foundation for targeted public …

Introduction The therapeutic landscape of chronic myeloid leukemia (CML) has evolved
significantly since the introduction of imatinib. The European LeukemiaNet (ELN) …

Simple Summary Chronic myeloid leukemia is a type of blood cancer that is regarded as a
success story in determining the exact biological origin, pathogenesis and development of a …

Chronic myeloid leukemia (CML), is one of the myeloproliferative disorders with a
characteristic cytogenetic abnormality resulting in the BCR-ABL fusion gene. Imatinib …

Background With the widespread clinical application of tyrosine kinase inhibitors (TKIs), an
increasing number of chronic myeloid leukaemia (CML) patients have developed resistance …

Chronic myeloid leukemia (CML) is caused by constitutively active fusion protein BCR-
ABL1, and targeting ABL1 is a promising therapy option. Imatinib, dasatinib, and nilotinib …